Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ivacaftor: Five-year outcomes in the West of Scotland cystic fibrosis population.

The clinical respiratory journal - 1 May 2023

Al-Din Yasmin, Dryden Carol, MacGregor Gordon, Young David, Coelho Cristina

Abstract excerpt

INTRODUCTION: Ivacaftor has shown to be effective in patients with cystic fibrosis (CF) with a G551D mutation. OBJECTIVES: This work aims to evaluate ivacaftor's effectiveness and safety in the real world, over 5 years, in the West of Scotland CF population. METHODS: We evaluated ivacaftor's effect on pulmonary function, body mass index (BMI), hospital bed occupancy, and adverse effects in patients ≥6 years with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adolescent
Share to Aminophenols
Share to Child

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Forced Expiratory Volume

Share to Mutation

Share to Quinolones

Source

Open in PubMed Open full text

Identifiers

PMID: 36938952
DOI: 10.1111/crj.13602
PMCID: PMC10214567

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ivacaftor: Five-year outcomes in the West of Scotland cystic fibrosis population.PMID 36938952Read ↗

VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations.Semantic proximity Read ↗

Real-world impact of ivacaftor in people with cystic fibrosis and select ivacaftor-responsive mutations.Semantic proximity Read ↗

Tezacaftor-ivacaftor use in routine care of adults with cystic fibrosis: a medicine use evaluation.Semantic proximity Read ↗

The impact of 12 months treatment with ivacaftor on Scottish paediatric patients with cystic fibrosis with the G551D mutation: a review.Semantic proximity Read ↗

Registry-based study in people with cystic fibrosis and an R117H variant treated with ivacaftor.Semantic proximity Read ↗

Longitudinal effects of ivacaftor and medicine possession ratio in people with the Gly551Asp mutation: a 5-year study.Semantic proximity Read ↗

Effects of ivacaftor in patients with cystic fibrosis who carry the G551D mutation and have severe lung disease.Semantic proximity Read ↗

Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.Semantic proximity Read ↗

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation.Semantic proximity Read ↗

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States.Semantic proximity Read ↗

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.Semantic proximity Read ↗

The use of lumacaftor/ivacaftor to treat acute deterioration in paediatric cystic fibrosis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.